Understand the source comparison
Adamax Men Over 40: Clinical Efficacy Comparison
Men 45–60, normal testosterone Adamax blend 200 mcg daily +42% vs baseline Lean mass +1.8 kg, fat mass −2.1 kg GI discomfort 8%, injection site reaction 5% Effective for receptor modulation without suppressing endogenous production; GI side effects mild and tr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Men 45–60, normal testosterone
- Adamax blend 200 mcg daily
- +42% vs baseline
- Lean mass +1.8 kg, fat mass −2.1 kg
- GI discomfort 8%, injection site reaction 5%
- Effective for receptor modulation without suppressing endogenous production; GI side effects mild and transient
- Men 50–70, low-normal testosterone
- TRT (testosterone cypionate 100 mg weekly)
- +12% vs baseline
- Lean mass +1.4 kg, fat mass −0.8 kg
- Polycythemia 18%, acne 12%, mood changes 9%
- Increases circulating hormone but doesn't address receptor density; polycythemia risk requires monitoring
- Men 40–65, borderline low testosterone
- Ipamorelin + CJC-1295 (no DAC) 250 mcg daily
- +38% vs baseline
- Lean mass +1.6 kg, fat mass −1.9 kg
- Transient flushing 6%, headache 4%
- Comparable IGF-1 response to full adamax blend; lower cost but lacks hexarelin cardioprotective component
- Men 55–75 with metabolic syndrome
- Placebo (saline injection)
- +2% vs baseline
- Lean mass +0.1 kg, fat mass +0.3 kg
- Injection site reaction 3%
- No metabolic benefit; confirms peptide-specific mechanism rather than placebo or injection-related effect